2. Natural Products
  3. Plants
  4. Cucurbitaceae
  5. Bolbostemma paniculaum (Maxim)Franguet

Bolbostemma paniculaum (Maxim)Franguet

Bolbostemma paniculaum (Maxim)Franguet (6):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N0890
    Tubeimoside I 102040-03-9 99.96%
    Tubeimoside I is an orally active HSPD1 inhibitor. Tubeimoside I inhibits NF-κB, MAPK, as well as regulates eNOS-VEGF. Tubeimoside I induces cytoprotective Autophagy via an Akt-mediated pathway. Tubeimoside I inhibits proinflammatory cytokine (IL-6 and IL-1β) production. Tubeimoside I exhibits anti-inflammatory activities. Tubeimoside I promotes angiogenesis and improves sepsis symptoms. Tubeimoside I is used in the research of inflammatory diseases, various cancers, sepsis and ischemic diseases.
    Tubeimoside I
  • HY-N2542
    Tubeimoside III 115810-13-4 99.91%
    Tubeimoside III, a triterpenoid saponin, shows anti-inflammatory, anti-tumor, anti-tumorigenic activities, and acute toxicity in vivo.
    Tubeimoside III
  • HY-N1932
    Bayogenin 6989-24-8 99.90%
    Bayogenin is an alfalfa saponin, shows moderate potency of glycogen phosphorylase inhibition.
    Bayogenin
  • HY-N1932R
    Bayogenin (Standard) 6989-24-8
    Bayogenin (Standard) is the analytical standard of Bayogenin. This product is intended for research and analytical applications. Bayogenin is an alfalfa saponin, shows moderate potency of glycogen phosphorylase inhibition.
    Bayogenin (Standard)
  • HY-N2542R
    Tubeimoside III (Standard) 115810-13-4
    Tubeimoside III (Standard) is the analytical standard of Tubeimoside III. This product is intended for research and analytical applications. Tubeimoside III, a triterpenoid saponin, shows anti-inflammatory, anti-tumor, anti-tumorigenic activities, and acute toxicity in vivo.
    Tubeimoside III (Standard)
  • HY-N0890R
    Tubeimoside I (Standard) 102040-03-9
    Tubeimoside I (Standard) is the analytical standard of Tubeimoside I. This product is intended for research and analytical applications. Tubeimoside I is an orally active HSPD1 inhibitor. Tubeimoside I inhibits NF-κB, MAPK, as well as regulates eNOS-VEGF. Tubeimoside I induces cytoprotective Autophagy via an Akt-mediated pathway. Tubeimoside I inhibits proinflammatory cytokine (IL-6 and IL-1β) production. Tubeimoside I exhibits anti-inflammatory activities. Tubeimoside I promotes angiogenesis and improves sepsis symptoms. Tubeimoside I is used in the research of inflammatory diseases, various cancers, sepsis and ischemic diseases.
    Tubeimoside I (Standard)